Guideline on the Prevention of Secondary Central Nervous System Lymphoma

This is a clinical practice guideline for patients undergoing first line therapy for lymphoma who are at risk for secondary central nervous system lymphoma. The guideline discusses risk factors and outlines management by CNS prophylaxis, with intrathecal (IT) methotrexate (MTX), systemic/intravenous high-dose methotrexate (HD-MTX), and folinic acid rescue discussed as treatment options. Outcomes of interest include risk of secondary central nervous system (CNS) lymphoma, incidence and timing of CNS relapse, treatment efficacy as measured by survival and CNS relapse, and treatment-related toxicity.